[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genedx Holdings Corp (WGS)

Genedx Holdings Corp (WGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,940,103
  • Shares Outstanding, K 29,289
  • Annual Sales, $ 427,540 K
  • Annual Income, $ -21,020 K
  • EBIT $ -13 M
  • EBITDA $ 12 M
  • 60-Month Beta 2.17
  • Price/Sales 4.78
  • Price/Cash Flow 30.47
  • Price/Book 6.63

Options Overview Details

View History
  • Implied Volatility 103.69% (-2.68%)
  • Historical Volatility 69.46%
  • IV Percentile 78%
  • IV Rank 62.43%
  • IV High 133.95% on 10/23/25
  • IV Low 53.41% on 08/28/25
  • Expected Move (DTE 7) 6.08 (9.28%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 22
  • Volume Avg (30-Day) 1,084
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 18,591
  • Open Int (30-Day) 13,005
  • Expected Range 59.42 to 71.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 1
  • High Estimate $-0.06
  • Low Estimate $-0.06
  • Prior Year $0.28
  • Growth Rate Est. (year over year) -121.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.18 +20.01%
on 03/27/26
73.46 -9.86%
on 04/21/26
-2.45 (-3.57%)
since 03/24/26
3-Month
55.18 +20.01%
on 03/27/26
106.76 -37.97%
on 01/27/26
-35.13 (-34.66%)
since 01/23/26
52-Week
55.17 +20.03%
on 05/08/25
170.87 -61.25%
on 12/02/25
-43.17 (-39.46%)
since 04/24/25

Most Recent Stories

More News
GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after...

WGS : 66.79 (+0.83%)
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDxâ„¢ and GenomeDxâ„¢ testing, regardless of the test result

WGS : 66.79 (+0.83%)
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

ZVRA : 10.05 (-0.59%)
WGS : 66.79 (+0.83%)
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinityâ„¢ and Real-World Genomic Leadership

GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact

WGS : 66.79 (+0.83%)
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

WGS : 66.79 (+0.83%)
GeneDx to Participate in Upcoming Investor Conferences

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:...

WGS : 66.79 (+0.83%)
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) ...

WGS : 66.79 (+0.83%)
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

Recognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes

WGS : 66.79 (+0.83%)
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens...

WGS : 66.79 (+0.83%)
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

WGS : 66.79 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn.

See More

Key Turning Points

3rd Resistance Point 72.29
2nd Resistance Point 70.29
1st Resistance Point 68.26
Last Price 66.79
1st Support Level 64.23
2nd Support Level 62.23
3rd Support Level 60.20

See More

52-Week High 170.87
Fibonacci 61.8% 126.67
Fibonacci 50% 113.02
Fibonacci 38.2% 99.37
Last Price 66.79
52-Week Low 55.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.